本帖最后由 老马 于 2012-1-13 21:20 编辑 0 ?) f) }5 L: S; _" a
) i& n0 l. n& _' X8 z爱必妥和阿瓦斯丁的比较
) G" M- Y/ t* Z. o0 M$ g+ h; c6 }
" K" T; d; ]! g
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
% ~' F5 Q2 n* _
, H& `6 m1 ?$ M/ V3 a% D5 C1 f
; s( Q& X6 C h( g; f0 H- ~
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/. |9 n/ a0 G& z; N2 W& D
==================================================! w! I9 ^7 n! w# i+ ^0 Q+ D9 c1 e
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)' o3 c# f4 g8 a3 u2 L$ n5 O
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.9 h- N0 q. T! E( l A: |7 z+ y' e
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* a0 W/ L- ^2 h O) M. D/ t( I; r- G8 }
|